Stockscreener 앱 받기
1.02
7.27%
-0.08
시장 영업 전:
1.01
-0.01
-0.98%
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
Coherus Sets Q1 2025 Earnings Date: How to Join the May 12 Conference Call - Stock Titan
Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Coherus to Participate in Upcoming Investor Conferences | CHRS S - GuruFocus
Coherus to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus BioSciences Sets Strong Presence at Top Healthcare Conferences: Key Oncology Updates Expected - Stock Titan
Coherus Presents Promising Early Clinical Data from Phase 1 Dose - GuruFocus
Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient - marketscreener.com
Coherus reports promising cancer treatment results - Investing.com
Coherus (CHRS) Advances Clinical Trial for Anti-CCR8 Antibody in Cancer Treatment | CHRS Stock News - GuruFocus
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - The Manila Times
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric Cancer - Nasdaq
Breakthrough Cancer Treatment: Coherus Drug Shows Promise in Hard-to-Treat Head and Neck Cancer Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Turn Down - The Globe and Mail
Coherus BioSciences announces CCO Paul Reider’s resignation By Investing.com - Investing.com India
Coherus BioSciences announces CCO Paul Reider’s resignation - Investing.com Australia
3 Reasons We Love Chart (GTLS) - The Globe and Mail
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com
Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN
Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com
Coherus completes strategic transformation - The Pharma Letter
Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com
Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire
Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio (PR Newswire) - Aktiellt
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire
Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan
Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener
Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India
Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph
Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st
Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan
Lobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Yahoo Finance
Coherus BioSciences, Inc. SEC 10-K Report - TradingView
Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale By Investing.com - Investing.com Australia
Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - insights.citeline.com
Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com India
0.39%
3.66%
자본화:
|
볼륨(24시간):